LVTX Stock Overview
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LAVA Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.64 |
| 52 Week High | US$6.47 |
| 52 Week Low | US$1.13 |
| Beta | 0.63 |
| 1 Month Change | -34.49% |
| 3 Month Change | 44.26% |
| 1 Year Change | 70.32% |
| 3 Year Change | -78.00% |
| 5 Year Change | n/a |
| Change since IPO | -81.54% |
Recent News & Updates
Shareholder Returns
| LVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.7% | 1.0% | 1.2% |
| 1Y | 70.3% | 0.7% | 24.9% |
Return vs Industry: LVTX exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: LVTX exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| LVTX volatility | |
|---|---|
| LVTX Average Weekly Movement | 26.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LVTX's share price has been volatile over the past 3 months.
Volatility Over Time: LVTX's weekly volatility has increased from 18% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Steve Hurly | www.lavatherapeutics.com |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
LAVA Therapeutics N.V. Fundamentals Summary
| LVTX fundamental statistics | |
|---|---|
| Market cap | US$69.40m |
| Earnings (TTM) | -US$41.97m |
| Revenue (TTM) | US$6.77m |
10.3x
P/S Ratio-1.7x
P/E RatioIs LVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LVTX income statement (TTM) | |
|---|---|
| Revenue | US$6.77m |
| Cost of Revenue | US$3.48m |
| Gross Profit | US$3.29m |
| Other Expenses | US$45.26m |
| Earnings | -US$41.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 48.56% |
| Net Profit Margin | -620.09% |
| Debt/Equity Ratio | 10.3% |
How did LVTX perform over the long term?
See historical performance and comparison